

# SESLHD POLICY COVER SHEET



**Health**  
South Eastern Sydney  
Local Health District

<b>NAME OF DOCUMENT</b>	SESLHD Research Fees
<b>TYPE OF DOCUMENT</b>	Policy
<b>DOCUMENT NUMBER</b>	SESLHDPD/332
<b>DATE OF PUBLICATION</b>	December 2021
<b>RISK RATING</b>	Low
<b>LEVEL OF EVIDENCE</b>	National Safety and Quality Health Service Standards: Standard 1 – Clinical Governance
<b>REVIEW DATE</b>	December 2026
<b>FORMER REFERENCE(S)</b>	N/A
<b>EXECUTIVE SPONSOR or EXECUTIVE CLINICAL SPONSOR</b>	Director, Research
<b>AUTHOR</b>	Marie Le Bechennec SESLHD Research Business Manager
<b>POSITION RESPONSIBLE FOR THE DOCUMENT</b>	SESLHD Research Business Manager <a href="mailto:Marie.LeBechennec@health.nsw.gov.au">Marie.LeBechennec@health.nsw.gov.au</a>
<b>FUNCTIONAL GROUP(S)</b>	Research
<b>KEY TERMS</b>	Research, Ethics, Governance, Human Research Ethics Committee (HREC), South Eastern Sydney Local Health District (SESLHD), Collaborative Research Committee (CRC)
<b>SUMMARY</b>	A SESLHD specific research fee policy is to be used in conjunction and accordance to the most current- NSW Ministry of Health (MoH) Policy Directive PD2008_030 - <i>Human Research Ethics Committee (HREC) and Research Governance: Fee Policy for Review of Commercially Sponsored Research</i>

**COMPLIANCE WITH THIS DOCUMENT IS MANDATORY**  
This Policy is intellectual property of South Eastern Sydney Local Health District.  
Policy content cannot be duplicated.

Feedback about this document can be sent to [SESLHD-Policy@health.nsw.gov.au](mailto:SESLHD-Policy@health.nsw.gov.au)

**1. POLICY STATEMENT**

A Fee Policy has been implemented in order to comply with [NSW Ministry of Health \(MoH\) Policy Directive PD2008\\_030 - Human Research Ethics Committee \(HREC\) and Research Governance: Fee Policy for Review of Commercially Sponsored Research](#) and provide a mechanism to fund the necessary operational and service improvement for the South Eastern Sydney Local Health District (SESLHD) and Human Research Ethics Committee (HREC) and Research Governance review to meet the NSW Office for Health and Medical Research (OHMR) Key Performance Indicators (KPIs).

**2. AIMS**

The policy has been implemented in order to ensure sufficient funds are available to deliver timely service that supports the activities of the SESLHD HREC and SESLHD Research and Governance Office. The policy is in alignment to the 2017-21 SESLHD Research Strategy objective to build research capacity in SESLHD, namely funding to support research within the LHD.

The funds supplement the supports provided by the SESLHD Research Office and are used to ensure quality governance and operational compliance (including salaries, administrative support and training) by the SESLHD HREC and Research Office to its obligations as directed by the National Health and Medical Research Council's (NHMRC) National Statement on Ethical Conduct in Research Involving Humans and the Australian Code for the Responsible Conduct of Research.

**3. TARGET AUDIENCE**

- 3.1 This policy applies to all researchers who submit documents to the SESLHD Research Office for review and approval to conduct research projects. This policy should be used in conjunction with the NSW Ministry of Health HREC and Research Governance: Fee Policy for Review of Commercially Sponsored Research (PD2008\_030) or until otherwise instructed by NSW Ministry of Health.
- 3.2 A SESLHD Research office fee form must be completed with all relevant details before the application can be eligible for review by the SESLHD Research Office and SESLHD HREC.
- 3.3 Funding contributors to the SESLHD Collaborative Research Committee (CQC) once acknowledged on application, will be waived of process fees.
- 3.4 There will be opportunity for case by case fee considerations at the discretion of Director, Research for exceptional cases.

### 4. RESPONSIBILITIES

- 4.1 SESLHD Director: responsible for the overall governance and regulation of the fee structure within the SESLHD Research Directorate.
- 4.2 SESLHD Research Ethics & Governance Manager: responsible for the monitoring and measuring of the research application eligibility process and training of the staff. Shared responsibility for the exceptional case by case discretion of the fees and/or waiver of fees.
- 4.3 SESLHD Research Business Manager: responsible for the monitoring, measurement and reporting of the billing process, generated revenue and shared responsibility of the case by case discretion and/or waiver of the fees.

### 5. DEFINITIONS

SESLHD has adopted the definitions from the [NSW Ministry of Health Policy Directive PD2011\\_006 - Clinical Trials - Insurance and Indemnity](#).

#### **5.1 A commercially sponsored research project has the following characteristics:**

- 5.1.1 It is initiated by a pharmaceutical/device company or other commercial entity and not by an investigator at a NSW public health service site.
- 5.1.2 The research is conducted to investigate a medication/device for commercial exploitation by its manufacturer/sponsor.
- 5.1.3 The protocol has been developed and is the responsibility of a pharmaceutical/device company or other commercial entity.

#### **5.2 A sponsored (non-commercial) research project has the following characteristics:**

- 5.2.1 The research must address relevant clinical questions and not pharmaceutical/device industry or commercial needs.
- 5.2.2 The sponsor (non-commercial) must declare any/in-kind support (e.g. provision of medicines, devices, funds) from any organisation.
- 5.2.3 The sponsor (non-commercial) must be the primary author and custodian of the clinical trial protocol

**5.3 Examples of groups that may fall under this category are;**

- 5.3.1 Research institutes external to NSW Health;
- 5.3.2 Collaborative or cooperative research groups external to NSW Health
- 5.3.3 Universities.

**5.4 An investigator initiated (SESLHD sponsored) research project has the following characteristics:**

- 5.4.1 A pharmaceutical/device company is not acting as the Sponsor for the purposes of the CTN Scheme application.
- 5.4.2 A pharmaceutical/device company is not directly funding the conduct of the study that is making payment to the relevant hospital or investigator.
- 5.4.3 The clinical trial addresses relevant clinical questions and not industry needs.
- 5.4.4 The Principal Investigator and SESLHD is the primary author and custodian of the clinical trial protocol. Note – Investigator initiated trials can receive some industry funding or industry contribution, (e.g. educational grants, or supply of medication). However, the support must be declared in the protocol submission and *method of payment form* to ensure that the clinical trial retain its ‘investigator initiated’ status and fee levy reviewed.

**5.5 Amendments to approved research**

Fees are applied to each version change to Investigators Brochures (or equivalent) and protocol documents (or equivalent). No additional fee applies for Participant Information Sheet and Consent Forms (PISCFs) submitted in conjunction with an updated protocol or IB. However, if PISCFs are submitted separately, the fee applies.

*Amendment definitions*

- 5.5.1 *Complex*: Substantial changes to the project requiring review by the full HREC, e.g. Change of aims and objectives, addition of a sub-study or open-label extension which was not part of the originally approved protocol.
- 5.5.2 *Regular*: Most amendments fall into this category, e.g. IB updates, protocol revision to modify visit schedule, revision in risk section of PISCF following IB update, extension of follow-up from 3 to 5 years, addition of new questionnaire.
- 5.5.3 *Minor*: Correction of typographical errors without movement of text, update to contact details. Fee levy may be discussed with Research Manager.

**6. DOCUMENTATION**

**SOUTH EASTERN SYDNEY RESEARCH OFFICE – METHOD OF PAYMENT FORM**

Please note that your submission will not be valid without correct completion of this form

*Fund contributors to the SESLHD Collaborative Research Committee – do not require payment.*

<b>1. ADMINISTRATIVE DETAILS</b>	
<b>1.1.1 DATE</b>	
<b>1.1.2 REFERENCE NUMBER</b> FOR ETHICS – YEAR/ETHXXXXX FOR GOVERNANCE – YEAR/STEXXXXX	
<b>1.1.3 STUDY TITLE</b>	
<b>1.1.4 ARE YOU OR THE PRINCIPAL INVESTIGATOR ON THIS PROJECT AN EXISTING RESEARCH FUND COMMITTEE MEMBER OR CONTRIBUTOR?</b> (I.E.: DO YOU MAKE DIRECT CONTRIBUTIONS THROUGH YOUR RFA ACCOUNT)	<b>YES</b> <input type="checkbox"/> <i>Fund contributors (i.e.: from Restricted Fund Assets) - please fill in cost centre details below for verification -no payment will not be required.</i> <b>NO</b> <input type="checkbox"/>
<b>1.1 PRINCIPAL INVESTIGATOR</b>	
<b>NAME</b>	
<b>EMAIL ADDRESS</b>	
<b>CONTACT NUMBER</b>	
<b>1.2 PERSON COMPLETING FORM</b>	<input type="checkbox"/> NOT APPLICABLE: AS ABOVE
<b>NAME</b>	
<b>EMAIL ADDRESS</b>	
<b>CONTACT NUMBER</b>	

<b>2. PAYMENT/INVOICE DETAILS</b>	
<b>2.1 PAYMENT TYPE</b>	<b>INTERNAL RFA TRANSFER</b> <input type="checkbox"/> <b>EXTERNAL FUNDING SOURCE</b> <input type="checkbox"/>
<b>2.2 INTERNAL RFA TRANSFER</b>	FUNDS WILL BE TRANSFERRED FROM COST CENTRE BELOW TO RESEARCH - 181333
<b>2.2.1 COST CENTRE NAME</b>	
<b>2.2.2 COST CENTRE NUMBER</b>	
<b>2.2.3 COST CENTRE SIGNATORY</b>	
<b>2.3 EXTERNAL FUNDING SOURCE</b>	INVOICES WILL BE DIRECTED TO THE NOMINATED PARTY BELOW
<b>2.3.1 Protocol Number</b>	
<b>2.3.2 FUNDING SOURCE NAME</b>	
<b>2.3.3 ABN (IF APPLICABLE)</b>	

# SESLHD POLICY

## SESLHD Research Fee Policy

## SESLHDPD/332

2.3.4 ADDRESS	
2.3.5 CONTACT NAME	
2.3.6 CONTACT NUMBER	
2.3.7 CONTACT EMAIL	

3. HREC/ETHICS APPLICATION SUBMISSION AND REVIEW FEES		
3.1.1 FUNDING CATEGORY	FEE	REQUESTED SERVICE
3.1.2 <b>COMMERCIALLY FUNDED PROJECT</b> REGARDLESS OF AMOUNT	<b>\$3,300</b>	YES <input type="checkbox"/>
3.1.3 <b>ADDITION OF SUB-STUDY TO RESEARCH PROJECTS WITH FULL COMMERCIAL FUNDING</b> SUB-STUDIES WILL BE REVIEWED AND FEE DETERMINED ON CASE BY CASE BASIS. THE HREC MAY REQUEST THE SUB-STUDY BE SUBMITTED AS A NEW APPLICATION AND CHARGE FULL FEE.	<b>\$1665</b>	YES <input type="checkbox"/>
3.1.3 <b>COLLABORATIVE PROJECT WITH \$50,000 OR MORE OF FUNDING</b>	<b>\$3,300</b>	YES <input type="checkbox"/>
3.1.4 <b>COLLABORATIVE PROJECT WITH FUNDING UNDER \$50,000</b>	<b>\$150</b>	YES <input type="checkbox"/>
3.1.5 <b>INVESTIGATOR INITIATED PROJECTS FOR SESLHD STAFF *INCLUDES STUDENTS</b>	<b>\$150</b>	YES <input type="checkbox"/>
3.1.6 <b>INVESTIGATOR INITIATED PROJECTS FOR EXTERNAL APPLICANTS</b>	<b>\$300</b>	YES <input type="checkbox"/>

\*SESLHD internal/external status open to discussion and the discretion of the Research Manager

4. ETHICS AMENDMENTS – POST APPROVAL		
4.1 FUNDING CATEGORY	FEE	REQUESTED SERVICE
4.1.1 <b>COMMERCIALLY FUNDED PROJECT</b> INCLUDES CHANGES TO PROTOCOL AND IB. PISCFs WILL BE CHARGED AS SEPARATE DOCUMENTS UNLESS THEY ARE SUBMITTED AS PART OF A PROTOCOL AMENDMENT	<b>\$550</b> PER AMENDED DOCUMENT	YES <input type="checkbox"/>
4.1.2 <b>COLLABORATIVE PROJECT WITH \$50,000 OR MORE OF FUNDING</b> SPONSOR BEING A RESEARCH INSTITUTE/UNIVERSITY/ OR OTHER COLLABORATIVE GROUP	<b>\$550</b> PER AMENDED DOCUMENT	YES <input type="checkbox"/>
4.1.3 <b>COLLABORATIVE PROJECT WITH FUNDING UNDER \$50,000</b>	<b>\$100</b>	YES <input type="checkbox"/>
4.1.4 <b>INVESTIGATOR INITIATED PROJECTS</b>	<b>\$100</b>	YES <input type="checkbox"/>

5. GOVERNANCE (SSA) APPLICATION SUBMISSION AND REVIEW FEES		
5.1 FUNDING CATEGORY	FEE	REQUESTED SERVICE
5.1.1 <b>COMMERCIALLY FUNDED PROJECT</b>	<b>\$3,740</b>	YES <input type="checkbox"/>
5.1.2 <b>COLLABORATIVE PROJECT WITH \$50,000 OR MORE OF FUNDING</b>	<b>\$3,740</b>	YES <input type="checkbox"/>
5.1.3 <b>COLLABORATIVE PROJECT WITH FUNDING UNDER \$50,000</b>	<b>\$500</b>	YES <input type="checkbox"/>
5.1.4 <b>INVESTIGATOR INITIATED PROJECTS</b> INCLUDES STUDENTS	<b>\$150</b>	YES <input type="checkbox"/>

6. GOVERNANCE AMENDMENTS – POST APPROVAL		
6.1 FUNDING CATEGORY	FEE	REQUESTED SERVICE
6.1.1 <b>COMMERCIALLY FUNDED PROJECT</b> INCLUDES CHANGES TO PROTOCOL, IB, PISCF, and CONTRACT VARIATIONS	<b>\$500</b>	YES <input type="checkbox"/>

**SESLHD Research Fee Policy**

**SESLHDPD/332**

6.1.2 <b>COLLABORATIVE PROJECT WITH \$50,000 OR MORE OF FUNDING</b> SPONSOR BEING A RESEARCH INSTITUTE/UNIVERSITY/ OR OTHER COLLABORATIVE GROUP	<b>\$500</b>	<b>YES <input type="checkbox"/></b>
6.1.3 <b>COLLABORATIVE PROJECT WITH FUNDING UNDER \$50,000</b>	<b>\$100</b>	<b>YES <input type="checkbox"/></b>
6.1.4 <b>INVESTIGATOR INITIATED PROJECTS</b>	<b>\$100</b>	<b>YES <input type="checkbox"/></b>

Disclaimer: This document is solely for use within South Eastern Sydney Local Health District and unauthorised dissemination or modification should not take place.

**7. REFERENCES**

- [NSW Ministry of Health Policy Directive PD2008\\_030 – HREC and Research Governance: Fee Policy for Review of Commercially Sponsored Research](#)
- [NSW Ministry of Health Policy Directive PD2011\\_006 – Clinical Trials – Insurance and Indemnity](#)
- SESLHD Research Strategy 2017-2021

**8. REVISION & APPROVAL HISTORY**

Date	Revision No.	Author and Approval
August 2021	DRAFT	Initial draft by Marie Le Bechenec.
September 2021	DRAFT	Draft for Comments period. Feedback incorporated.
October 2021	DRAFT	Approved by Executive Sponsor. To be tabled at Clinical and Quality Council for approval.
December 2021	1	Approved at Clinical and Quality Council.